Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Bought by FNY Investment Advisers LLC

FNY Investment Advisers LLC grew its stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 160.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 477,823 shares of the biopharmaceutical company’s stock after purchasing an additional 294,323 shares during the period. FNY Investment Advisers LLC’s holdings in Revance Therapeutics were worth $1,452,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of RVNC. Bank of New York Mellon Corp increased its stake in Revance Therapeutics by 22.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 373,015 shares of the biopharmaceutical company’s stock valued at $959,000 after purchasing an additional 68,451 shares in the last quarter. Rhumbline Advisers increased its position in shares of Revance Therapeutics by 11.6% in the second quarter. Rhumbline Advisers now owns 136,347 shares of the biopharmaceutical company’s stock valued at $350,000 after buying an additional 14,191 shares in the last quarter. Arizona State Retirement System increased its position in shares of Revance Therapeutics by 27.6% in the second quarter. Arizona State Retirement System now owns 27,716 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 5,996 shares in the last quarter. Los Angeles Capital Management LLC raised its stake in shares of Revance Therapeutics by 25.2% during the 2nd quarter. Los Angeles Capital Management LLC now owns 116,368 shares of the biopharmaceutical company’s stock worth $299,000 after buying an additional 23,450 shares during the last quarter. Finally, Federated Hermes Inc. boosted its position in shares of Revance Therapeutics by 43.0% in the 2nd quarter. Federated Hermes Inc. now owns 2,237,505 shares of the biopharmaceutical company’s stock worth $5,750,000 after buying an additional 672,803 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Stock Up 1.2 %

Shares of Revance Therapeutics stock opened at $3.29 on Tuesday. The firm has a market cap of $343.44 million, a PE ratio of -1.70 and a beta of 0.86. Revance Therapeutics, Inc. has a fifty-two week low of $2.30 and a fifty-two week high of $7.56. The business’s fifty day moving average is $3.61 and its two-hundred day moving average is $4.54.

Revance Therapeutics (NASDAQ:RVNC) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $67.73 million. Equities research analysts anticipate that Revance Therapeutics, Inc. will post -1.57 EPS for the current year.

Analyst Ratings Changes

RVNC has been the subject of several recent research reports. Barclays dropped their target price on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a report on Monday, December 23rd. HC Wainwright reissued a “neutral” rating and set a $6.60 price objective on shares of Revance Therapeutics in a research note on Friday, November 8th. Mizuho reduced their target price on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research note on Tuesday, December 10th. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research report on Friday, November 8th. Finally, StockNews.com started coverage on Revance Therapeutics in a report on Monday. They issued a “hold” rating for the company. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.39.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.